Treatments Targeting LRRK2 Not Likely to Damage Organs, Study Finds

Treatments Targeting LRRK2 Not Likely to Damage Organs, Study Finds
People carrying gene variants that lower leucine-rich repeat kinase 2 (LRRK2) levels — an enzyme whose mutated form is one of the most common genetic causes of Parkinson’s disease — live as long as those without such variants, and show no related lung, liver or kidney damage, results of a large genetic study show. These findings give support to recent clinical trials testing molecules that block ... read more
Source: Parkinson’s News TodayPublished on 2020-06-03By Patricia Inacio, PhD